Company intelligence / Profile preview

CasInvent Pharma

Ownership: Private
Development stage: Preclinical

Overview

CasInvent Pharma has developed highly selective small-molecule inhibitors of the casein kinase 1 family. Their lead program(s) are in preclinical development with proof-of-concept studies ongoing for pancreatic cancer and other resistant tumors. The company has demonstrated promising data in eradicating leukemic cells and enhancing responses to chemotherapy in preclinical models. They are preparing for IND/CTA-enabling studies as part of a Eurostars-funded consortium.[1][5][6]

Therapeutic areas: Oncology
Modalities: Small molecules (selective CK1 inhibitors)[1][2][5][10]
Industry: Biotech

Drug pipeline

4 assets

CI2420B

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

i&i Prague, s.r.o.[3]University of Bern – PANC‑CKI consortium partner for organoid screening and validation [6]

Beyond the preview

Go deeper on CasInvent Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CasInvent Pharma.

Explore the full profile